Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer

Prognostic significance of p21WAF1/CIP1, p16INK4a and CD44s in tongue cancer

The role of lost or reduced expression of p21, p16 and CD44s in the survival of tongue cancer patients was investigated. Tumours and adjacent non-tumour epithelia (ANTE) from 36 patients with tongue cancer were retrospectively studied by immunohistochemistry using monoclonal antibodies against p21,...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncology reports 2007-08, Vol.18 (2), p.389-396
Hauptverfasser: GONZALEZ -MOLES, M. A, GIL-MONTOYA, J. A, RUIZ-AVILA, I, ESTEBAN, F, DELGADO-RODRIGUEZ, M, BASCONES-MARTINEZ, A
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Aged, 80 and over
Biological and medical sciences
Cyclin-Dependent Kinase Inhibitor p16 - analysis
Cyclin-Dependent Kinase Inhibitor p21 - analysis
Epithelium - chemistry
Epithelium - pathology
Female
Humans
Hyaluronan Receptors - analysis
Immunohistochemistry
Male
Medical sciences
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local
Otorhinolaryngology. Stomatology
Prognosis
Survival Analysis
Survival Rate
Tongue Neoplasms - metabolism
Tongue Neoplasms - mortality
Tongue Neoplasms - pathology
Tumors
Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The role of lost or reduced expression of p21, p16 and CD44s in the survival of tongue cancer patients was investigated. Tumours and adjacent non-tumour epithelia (ANTE) from 36 patients with tongue cancer were retrospectively studied by immunohistochemistry using monoclonal antibodies against p21, p16 and CD44s proteins. Expression of p21, p16 and CD44s and their relationship with clinical and pathological parameters were analyzed. Of 36 patients, 12 (33.33%) developed recurrence and 12 died of the disease (mean survival, 25.5 months). In four cases (11.1%), concomitant low expression (
ISSN:1021-335X
1791-2431
DOI:10.3892/or.18.2.389